The Journal of Prevention of Alzheimer's Disease最新文献

{"title":"Characterization of a metabolomics signature of the brain-health-promoting MIND diet in older persons.","authors":"Jeanne Neuffer, Raúl González-Domínguez, Sophie Lefèvre-Arbogast, Dorrain Y Low, Alba Tor-Roca, Catherine Helmer, Andrea Du Preez, Chiara de Lucia, Silvie R Ruigrok, Barbara Altendorfer, Ludwig Aigner, Paul J Lucassen, Aniko Korosi, Sandrine Thuret, Claudine Manach, Mercè Pallàs, Alex Sánchez-Pla, Cristina Andres-Lacueva, Mireia Urpi-Sarda, Cécilia Samieri","doi":"10.1016/j.tjpad.2026.100670","DOIUrl":"10.1016/j.tjpad.2026.100670","url":null,"abstract":"<p><strong>Background: </strong>The MIND diet supports healthy cognitive aging. Yet, a challenge remains to identify individuals who do not adhere to the MIND and could be at risk for accelerated cognitive decline. A multi-metabolite biomarker panel could facilitate population screening.</p><p><strong>Objectives: </strong>To determine and validate a blood metabolomics signature of MIND adherence in a large cohort of older adults, and to estimate its association with subsequent cognitive decline.</p><p><strong>Design, setting and participants: </strong>Participants were older adults (≥65 years) from the population-based three-City (3C) cohort, free of dementia at study baseline and followed for up to 12 years for cognition, who were included in two case-control samples on cognitive decline nested within two centers (Bordeaux and Dijon cities, n = 838).</p><p><strong>Exposures: </strong>155 diet-related serum metabolites measured with a multianalyte metabolomics platform.</p><p><strong>Main outcomes and measurements: </strong>The primary outcome was adherence to the MIND diet, assessed in a subsample of 344 participants from Bordeaux center (which underwent the dietary surveys, 24 h recall and food-frequency questionnaire). A metabolomics signature of MIND diet adherence was characterized with penalized regression and a metabolomics score (\"metaboscore\") reflecting the overall MIND biological fingerprint was calculated. The secondary outcome was cognitive decline status (coded as binary: accelerated, vs. null or minimal decline) over follow-up, assessed using repeated cognitive measures in the two case-control samples. The metaboscore was reconstructed and linked to the odds of cognitive decline.</p><p><strong>Results: </strong>Eight metabolites were identified: three were associated with higher MIND adherence (3-hydroxyhippuric acid, 5-hydroxyindole-3-acetic acid, betaine - phenolic acids and amino acid related to plant foods) and five with lower MIND adherence (1-methylhistidine from red meat; cyclo(L-leucyl-L-prolyl) from coffee; tartaric acid from wine; myristoyl-carnitine and dehydroepiandrosterone sulfate, endogenous). The French-MIND metaboscore was linked to lower odds of cognitive decline, although replication was not statistically significant after multivariable adjustment.</p><p><strong>Conclusion: </strong>A novel metabolomic signature of the MIND diet was characterized, which may help screen older adults at risk of poor brain nutrition and could support personalized dietary prevention strategies.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"13 10","pages":"100670"},"PeriodicalIF":7.8,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13586864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep complaints and genetic risk of Alzheimer's disease in older women: associations with memory and tau deposition.","authors":"Kitty K Lui, Xin Wang, Melanie A Dratva, Ella T Lifset, Jordan Stiver, Nadine C Heyworth, Qian Shen, Michael Thomas, Pamela N DeYoung, Atul Malhotra, Erin E Sundermann, Sarah J Banks","doi":"10.1016/j.tjpad.2026.100581","DOIUrl":"10.1016/j.tjpad.2026.100581","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence point to a bidirectional relationship between sleep disturbances and Alzheimer's disease (AD). Poor sleep may be an overlooked risk factor for older women, who are disproportionately affected by AD and report worse subjective sleep quality than men. High genetic AD risk-characterized by the polygenic hazard score (PHS), including apolipoprotein (APOE) ε4 carriership-may further compound the effects of disrupted sleep on AD, particularly for older women.</p><p><strong>Objective: </strong>This study examined the moderating effect of genetic AD risk on subjective sleep as it related to memory and tau burden in a sample of older women.</p><p><strong>Participants: </strong>The sample consisted of older women (≥65 years old) from the Women Inflammation Tau Study.</p><p><strong>Measurement: </strong>Participants completed the Pittsburgh Sleep Quality Index (PSQI), Rey Auditory Learning Test, and Brief Visuospatial Memory Test-Revised. They also underwent [18]F-MK6240 positron emission tomography. Tau burden was calculated in composite regions across Braak stages. Genetic risk groups were characterized by PHS stratified at the 75th percentile. PSQI global score × PHS group interactions on memory composite scores (N = 69) and tau burden (N = 63) were examined.</p><p><strong>Results: </strong>PSQI global score × PHS group interactions were observed on visual memory and pathological tau in Braak regions III/IV (ps<0.10). Poorer subjective sleep was associated with worse visual memory and greater limbic tau deposition only among higher genetic risk women (ps<0.04). No significant associations were observed for verbal memory or tau in Braak regions I/II or V/VI.</p><p><strong>Conclusion: </strong>Older women with elevated genetic AD risk and subjective sleep difficulties may be at greater risk for visual memory deficits and tau burden in regions affected in early AD. This suggests that sleep complaints may represent a promising AD risk factor. Improving sleep may be a potential intervention target for AD mitigation and prevention, particularly for older women.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"13 7","pages":"100581"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13156732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertension acts together with Aβ pathology in late-life to promote memory loss.","authors":"Lucas U Da Ros, João Pedro Ferrari-Souza, Marco Antônio de Bastiani, Lucas A Hauschild, Bruna Bellaver, Pamela C L Ferreira, Douglas Teixeira Leffa, Guilherme Povala, Firoza Z Lussier, Mira Chamoun, Gleb Bezgin, Andrea L Benedet, Nesrine Rahmouni, Arthur C Macedo, Kaj Blennow, Nicholas Ashton, Henrik Zetterberg, Wyllians Vendramini Borelli, Diogo O Souza, Tharick A Pascoal, Pedro Rosa-Neto, Eduardo R Zimmer","doi":"10.1016/j.tjpad.2026.100579","DOIUrl":"10.1016/j.tjpad.2026.100579","url":null,"abstract":"<p><p>Midlife hypertension (HTN) contributes to cognitive decline in Alzheimer's disease (AD). However, the exact effect of late-life HTN on the AD pathology and on cognitive decline is still controversial. Here, we aimed to assess the impact of HTN and AD pathology in cognitively unimpaired (CU) individuals over 65 years of age on longitudinal cognitive decline. We evaluated 637 CU individuals from two independent cohorts (475 CU individuals from the ADNI cohort; and 162 CU individuals from the TRIAD cohort), with a follow-up of up to 6 years. Linear mixed-effects models showed that HTN and Aβ acted together to promote longitudinal cognitive decline, especially memory loss, in a synergistic way, with a dose-dependent association of blood pressure and Aβ pathology. Hence, HTN in late-life confers additional risk for cognitive decline, particularly for memory loss, in CU individuals at risk of developing dementia due to AD and is a potential modifiable risk factor even at older age.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"13 7","pages":"100579"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13217599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148006858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond target engagement: RNA therapeutics and the neuroimmune challenge in tauopathies.","authors":"Elizabeth Anne Breen","doi":"10.1016/j.tjpad.2026.100626","DOIUrl":"10.1016/j.tjpad.2026.100626","url":null,"abstract":"<p><p>Recent advances in RNA-based therapeutics have generated considerable interest as a strategy for targeting tau pathology in Alzheimer's disease and related tauopathies. In their review, Rajbanshi and colleagues provide a comprehensive overview of emerging RNA therapeutic modalities, translational challenges, and ongoing clinical development efforts. This commentary discusses the promise of RNA-based approaches within the broader context of contemporary neurodegeneration research, highlighting the persistent disconnect between molecular target engagement and meaningful clinical benefit. Emerging evidence suggests that successful disease modification may require consideration of neuroimmune dysfunction, biological heterogeneity, and disease stage in addition to molecular pathology. The future success of RNA therapeutics will likely depend not only on achieving precise modulation of tau biology but also on translating these advances into sustained cognitive and functional benefit for patients.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"13 7","pages":"100626"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13284461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148259676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma brain-derived p-Tau217 outperforms other p-Tau species in detecting abnormal brain amyloid in an Asian cohort of older people with cerebrovascular disease burden.","authors":"Joyce R Chong, Saima Hilal, Narayanaswamy Venketasubramanian, Michael Schöll, Nicholas J Ashton, Henrik Zetterberg, Christopher P Chen, Mitchell K P Lai","doi":"10.1016/j.tjpad.2026.100615","DOIUrl":"10.1016/j.tjpad.2026.100615","url":null,"abstract":"<p><strong>Background: </strong>Plasma brain derived-p-Tau217 (BD-p-Tau217) may outperform total-p-Tau217 in detecting brain amyloid burden and warrants evaluation.</p><p><strong>Objectives: </strong>To perform head-to-head comparison of plasma BD- as well as total-p-Tau181, p-Tau217 and p-Tau231 for detecting beta-amyloid positivity (Aβ+), evaluate reference ranges for Aβ+, and assess the prognostic utility of BD-p-Tau217 reference ranges.</p><p><strong>Design: </strong>Observational study.</p><p><strong>Setting: </strong>Participants recruited from memory clinics and the community in Singapore.</p><p><strong>Participants: </strong>213 participants, including 44 cognitively normal, 107 cognitively impaired no dementia, and 62 dementia (mean [SD] age, 73 [1] years; 121 females).</p><p><strong>Measurements: </strong>Amyloid status (Aβ- [n = 139] vs Aβ+ [n = 74]) was determined by positron emission tomography (PET). Plasma BD-p-Tau and total-p-Tau were measured using the NULISAseq™ CNS Disease Panel 120. The diagnostic performance for detecting Aβ+, reference ranges (three-range: 95% specificity/95% sensitivity); binary: maximizing Youden index), and the prognostic performance of p-Tau biomarkers were evaluated.</p><p><strong>Results: </strong>Plasma BD-p-Tau217 (AUC = 0.965) outperformed other BD- and total-p-Tau species in detecting PET Aβ+ (AUC = 0.823-0.937; all p ≤ 0.008). Using a three-range reference, BD-p-Tau217 achieved positive predictive value (PPV) and negative predictive value (NPV) of 90% and 97%, respectively. Proportion of participants in the intermediate-risk group was 7% (n = 14). Applying a binary reference, BD-p-Tau217 achieved both a specificity and sensitivity of 92%, with PPV and NPV of 86% and 96%, respectively. BD-p-Tau217-derived high-risk group exhibited faster cognitive decline than the low-risk group.</p><p><strong>Conclusions: </strong>Risk stratification for PET Aβ+ based on plasma BD-p-Tau217 suggests superior diagnostic and prognostic utility, warranting further validation.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"13 7","pages":"100615"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13264343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148176780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eligibility of men vs. women in Alzheimer's trials: Inclusive vs. representative.","authors":"Joshua D Grill, Daniel L Gillen","doi":"10.1016/j.tjpad.2026.100625","DOIUrl":"10.1016/j.tjpad.2026.100625","url":null,"abstract":"","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"13 7","pages":"100625"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13279289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148253347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virtual reality-based training in patients with alzheimer's disease: A systematic review and meta-analysis.","authors":"Junjie Wang, Can Wu, Kedong Zhu, Xiaoshan Qi, Guiqin Chen","doi":"10.1016/j.tjpad.2026.100590","DOIUrl":"10.1016/j.tjpad.2026.100590","url":null,"abstract":"<p><strong>Background and objectives: </strong>Prior meta-analyses have suggested that training utilizing virtual reality (VR) serves as a secure and effective intervention for elderly individuals experiencing mild cognitive impairment (MCI). Nevertheless, the effectiveness of such interventions appears to differ among various populations and cognitive domains. Furthermore, there remains a significant gap in understanding the effectiveness of VR-based training, specifically among individuals diagnosed with Alzheimer's disease (AD).</p><p><strong>Methods: </strong>The researchers conducted a comprehensive search of databases, including Web of Science, PubMed, Cochrane Library, and EMBASE up until July 1, 2025, focusing on randomized controlled trials that investigated VR-based training in patients diagnosed with AD. The outcomes measured were categorized and analyzed separately, encompassing overall cognitive performance, distinct cognitive domains, psychosocial function, physical capabilities, and the execution of daily living activities within the context of AD trials.</p><p><strong>Results: </strong>Of the 265 publications identified, 11 (4.15%) randomized controlled trials (RCTs) eventually met all eligibility criteria. Those who received VR-based training showed significantly better global cognitive function [SMD (95%CI) = 0.44 (0.21-0.68)] and Short-term memory [SMD (95%CI) = 0.62 (0.25-0.99)] than the controls. However, no significant improvements were observed in areas such as executive function, spatial memory, activities of daily living, quality of life, balance and coordination, fear of falling, risk of falls, and depression levels.</p><p><strong>Conclusion: </strong>VR-based interventions demonstrated beneficial effects on global cognitive function and short-term memory in AD populations. Due to the small sample size, the current research on evidence for efficacy in people with AD is weak and limited in many indicators.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"13 7","pages":"100590"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13157051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asia's dementia burden: from epidemiological description to prevention-oriented neurology.","authors":"Haoyang Hu","doi":"10.1016/j.tjpad.2026.100627","DOIUrl":"10.1016/j.tjpad.2026.100627","url":null,"abstract":"","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"13 7","pages":"100627"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13312470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148296409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tetanus, diphtheria and pertussis vaccination and risk for incident dementia among adults with down syndrome.","authors":"Kimberly Schiel, Joanne Salas, Anjani Urban, Daniel F Hoft, Jeffrey F Scherrer","doi":"10.1016/j.tjpad.2026.100583","DOIUrl":"10.1016/j.tjpad.2026.100583","url":null,"abstract":"<p><strong>Background: </strong>Adult vaccination is inversely associated with incident Alzheimer's Disease and Related Dementias.</p><p><strong>Objectives: </strong>We determined if Tetanus, Diphtheria and Pertussis (Tdap) vaccination was linked to incident Alzheimer's Disease and dementia among adults with Down Syndrome, 50% of whom develop Alzheimer's Disease by age 60.</p><p><strong>Design: </strong>This is a retrospective cohort study using TriNetX nationally distributed electronic health records from 2013 to 2024.</p><p><strong>Setting: </strong>Historical medical record data.</p><p><strong>Participants: </strong>5591 patients with Down Syndrome across the United States. Eligible patients were free of Alzheimer's Disease and dementia prior to index. Index date could occur 1/1/2015 to 1/1/2020 allowing for 5 to 10 years of possible follow-up time.</p><p><strong>Measurements: </strong>Vaccination was measured using product name and procedure codes and Alzheimer's Disease and dementias was defined by ICD-10 codes.</p><p><strong>Results: </strong>The mean age of the cohort was 50.0 (±8.3), 50.1% were female and 72.1% were White. After controlling for confounding, Tdap vaccination vs. remaining without Tdap vaccination was associated with lower Alzheimer's Disease and dementia risk (HR=0.74; 95%CI:0.57-0.98).</p><p><strong>Conclusions: </strong>In a cohort of patients with Down Syndrome, Tdap vaccination was associated with a 26% lower risk for Alzheimer's Disease and dementia. This is a novel and important finding because existing studies of vaccination and reduced risk for Alzheimer's Disease and dementia have been among cognitively intact adults. This study reveals benefits of vaccination even among those at high risk for Alzheimer's Disease and dementia due to Down Syndrome. Future studies are needed to understand the mechanisms underlying this relationship.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"13 7","pages":"100583"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of an automated plasma p-tau217 chemiluminescent assay for detecting Aβ pathology in a Chinese memory clinic cohort.","authors":"Shuai Chen, Feng-Yu Wang, Rong Li, Chang Fu, Jing-Yu Shao, Yu Shen, Kai Ma, Xiao-Di Hao, Lin Cao, Jun-Ling Xu, Jie-Wen Zhang","doi":"10.1016/j.tjpad.2026.100613","DOIUrl":"10.1016/j.tjpad.2026.100613","url":null,"abstract":"<p><strong>Background: </strong>Blood-based biomarkers have emerged as promising tools for detecting Alzheimer's disease (AD) pathology, but validation of automated plasma assays in Chinese clinical populations remains limited. This study evaluated the diagnostic performance of a fully automated chemiluminescent plasma biomarker assay for detecting amyloid-β (Aβ) pathology in a Chinese memory clinic cohort under different pre-analytical conditions.</p><p><strong>Methods: </strong>We enrolled 409 cognitively impaired participants from a single-center memory clinic, using amyloid-β positron emission tomography (Aβ-PET) as the reference standard. Plasma samples were analyzed under two pre-analytical conditions: frozen batch-processed samples from a historical cohort (n = 198) and freshly collected samples analyzed in real time in a prospective cohort (n = 211). Additionally, 95 participants underwent tau-PET imaging. Six plasma biomarkers were quantified using the Vazyme® AD Assay.</p><p><strong>Results: </strong>Across cohorts, p-tau217, p-tau217/Aβ42 ratio, and NfL/p-tau217 ratio consistently achieved excellent diagnostic performance (AUCs 0.92-0.95), followed by p-tau181 (AUCs 0.86-0.90). GFAP (AUCs 0.82-0.83) and the Aβ42/40 ratio (AUCs 0.76-0.81) showed moderate discriminative performance. Plasma p-tau217 alone achieved diagnostic accuracy comparable to composite biomarker models. A dual cut-point strategy reduced the indeterminate zone to <30%, with positive predictive values of 0.97-0.99 and negative predictive values of 0.86-0.87. Plasma p-tau217 was also significantly associated with tau-PET burden in both meta-temporal and neocortical regions (P < 0.001).</p><p><strong>Conclusion: </strong>This automated chemiluminescent plasma biomarker assay demonstrated high diagnostic accuracy for detecting Aβ pathology in a Chinese memory clinic cohort under different pre-analytical conditions. The findings support its potential utility as a practical blood-based biomarker approach in specialized clinical settings, while further multicenter studies are needed to confirm its generalizability across broader populations and healthcare environments.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"13 7","pages":"100613"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13266171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148176850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}